HIV and AIDS memorial garden unveiled in Leicester
A memorial garden dedicated to those who are living with HIV or have lost their lives to AIDS has been officially opened in Leicester.
The garden, beside Holy Trinity Church in Leicester, was funded by East Midlands Sexual Health, formerly known as Leicester Aids Support Services (LASS).
Organisers said the garden honoured those who died during the early days of the HIV epidemic in the city.
"We must never forget the brave souls who lost their lives in the early days of the epidemic, and those who stood by them," said Lee Brooker, former service user and employee of East Midlands Sexual Health.
Alistair Hudson, former chief executive of East Midlands Sexual Health, said he believed the garden was one of seven memorials to HIV and AIDS across the UK.
It is also hoped the garden will be a symbol of progress in the treatment of HIV.
"As we look back on this, HIV will be remembered as one of the greatest public health success stories in the last 100 years," he said.
"It informed the Ebola response and the Covid response. A cure will be the next major milestone."
The garden is one of six legacy projects supported by East Midlands Sexual Health, by funds raised from the sale of its building after it closed down in 2023.
Gavin Brown, chief executive of the Leicester-based Trade Sexual Health charity, said: "We organise a Red Ribbon Remembrance on World AIDS Day every year.
"In future years, we'll be gathering here on 1 December to remember the people we've lost but also to recommit ourselves to continuing to fight for the living and ensure an end to the HIV crisis."
Follow BBC Leicester on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
UK Aids Memorial Quilt to be shown at Tate Modern
Aids memorial quilt display aims to 'break stigma'
HIV and Aids memorial to be 'a beacon of hope'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration reportedly plans to cut almost all funding for HIV vaccine research. Experts say the decision comes at a time when research in this field is making substantial progress. Many effective treatments are available for HIV, but these are lifelong commitments that manage a chronic disease rather than cure it. Treatments for HIV infection have come a long way since the 1980s, when too many lives were lost during the epidemic. Today, antiretroviral therapies and other treatments allow people with HIV to live longer lives and, in many cases, prevent the transmission of the virus that causes the disease to other people. Scientists now say the next step in the fight is a vaccine that protects against HIV. However, that next development could be on the chopping block. Trump administration officials reportedly plan to halt funding for a wide array of HIV vaccine research. Researchers told CBS News they have been informed by officials at the National Institutes of Health (NIH) that the Department of Health and Human Services (HHS) has instructed the agency not to issue any more funding during the next fiscal year for HIV vaccine research. NIH officials said HHS officials have instead decided to 'go with currently available approaches to eliminate HIV.' The decision will close down HIV vaccine research projects at the Duke Human Vaccine Institute and the Scripps Research Institute, according to a report in the journal Science. Officials at Moderna also told CBS News that their current clinical trials on HIV vaccines have been put on hold. Experts say the decision to cut funding for an HIV vaccine is short-sighted and reckless. 'I'm stunned by this decision,' said Jake Scott, MD, a clinical associate professor of medicine at Stanford University in California who specializes in infectious diseases. 'There is no scientific or medical evidence to justify these cuts at the exact moment this field is showing real promise,' he told Healthline. Carl Baloney Jr., the chief executive officer-elect of AIDS United, agreed. 'Eliminating funding for HIV vaccine research undermines decades of scientific progress and turns our back on a future where HIV could be preventable for all, regardless of where someone lives, their income, or access to healthcare,' he told Healthline. Why an HIV vaccine is important Experts say that treatments for HIV are incredibly effective. However, they note that most involve daily adherence and aren't necessarily readily available or affordable for many people. 'There are a lot of good options, but they can be really expensive,' Scott said. 'These medications are also not a cure. They are a lifetime burden.' The experts add that people with low levels of HIV in their system can still have weakened immune systems. That can raise the risk of serious infections as well as inflammation that can lead to conditions such as heart disease. 'A vaccine can help prevent all this,' said Scott. Experts note that a vaccine research program may be difficult to put back together even if a new administration restored funding in the near future. They say it took decades to build these programs and restarting them would take time. In addition, researchers will leave the field of HIV prevention to set up shop in another industry that is receiving funding. 'We could lose an entire generation of scientists,' said Scott. 'This is setting the field back a decade or more at a critical time.' 'This isn't just about canceling [a] clinical trial. It's about sidelining the scientists, institutions, and community partners driving innovation forward,' added Baloney. 'These setbacks could delay the development of a successful HIV vaccine by years or even decades.' How scientists fought against HIV The first treatment for HIV was approved by the Food and Drug Administration (FDA) in 1987. Azidothymidine (AZT) was first developed in 1964 as a treatment for cancer. It was ineffective in that usage, but in the 1980s, scientists discovered AZT could suppress HIV replication without damaging healthy cells. It helped treat people with AIDS as well as people who were HIV positive but had no symptoms. In the 1990s, other nucleoside reverse transcriptase inhibitors (NRTIs) were developed and approved. Laboratory tests to measure viral load and cell counts accelerated this research. From there, scientists experimented with combining drugs to help counter the HIV virus's ability to mutate and replicate. In 1996, a triple-drug therapy proved effective in thwarting HIV replication and creating a barrier against drug resistance. Since then, these antiretroviral drugs have become more effective and more available. The effectiveness of these medications is nothing short of miraculous. In the 1980s, the average life expectancy after an AIDS diagnosis was one year. Today, people who adhere to combination antiretroviral drug therapies can expect to live a near-normal life span. In some cases, the medications can reduce the HIV viral load in a person to the point where the virus is undetectable and can't be transmitted to another person. How is HIV treated today? More than 50 types of HIV medications are now approved for use. Some of the more commonly used antiretroviral medications are: Combination NRTI drugs that include Truvada and Descovy. These medications work by preventing HIV from converting its RNA into DNA. This prevents the virus from making copies of itself.. Integrase strand transfer inhibitors (INSTIs) that include Vocabria and Biktarvy. These drugs work by blocking an enzyme that HIV uses to put HIV DNA into human DNA inside cells. Protease inhibitors (PIs) such as Lexiva and Crixivan. These medications work by blocking an enzyme that HIV needs as part of its life cycle. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that include Intelence and Viramune. These drugs work by preventing the HIV virus from making copies of itself. Entry inhibitors such as Fuzeon and Selzentry. These medications work by blocking HIV from entering CD4 T cells. In addition, there are drugs known as Cytochrome P4503A (CYP3A) inhibitors, such as Tybost and Norvir, that help boost the levels of HIV medications in the bloodstream. There are also medications known as post-attachment inhibitors that when used with antiretroviral drugs can help prevent HIV from entering immune cells. Trogarzo was the first of these drugs to become available, having been approved in 2018. In addition, there are attachment inhibitor medications, a newer form of HIV drug that works by attaching to a viral protein, which prevents that protein from entering healthy T cells. Only one type of this medication, Rubokia, is currently available, having been approved in 2020. Most people with HIV are given medications, but there also are long-acting injections that are given once a month or once every other month. Scott said these treatments are cures that have turned HIV into a 'managed chronic disease' to the point where he and other colleagues now refer to AIDS as 'advanced HIV.' Baloney said, however, there are limits to how much treatments can do. 'Current treatments and prevention tools have transformed HIV into a manageable chronic condition, but they are not a cure and they're not accessible to everyone,' he said. 'An HIV vaccine would be a game-changer, especially for communities facing systemic barriers to care.' Preventive measures for HIV Even with the available treatments, experts agree that it's better for a person if they don't contract HIV in the first place. They say condom use, along with dental dams and gloves, can be effective barriers to contracting HIV. Limiting sexual partners is also recommended, as are sterile needles for intravenous drug users. Getting tested for HIV is also an important component. It's estimated that more than 1 million people in the United States have HIV, and 13% of them don't know they have contracted the virus. There are medications available that can be taken as a precaution or after potential exposure to HIV. These drugs include: Preexposure prophylaxis (PrEP): These medications can be taken as a daily pill or a bimonthly injection. The first injectable PrEP drug was Apretude, which was approved by the FDA in 2021. Truvada can also be used as PrEP therapy. These medications help prevent HIV from getting a foothold in the body. Postexposure prophylaxis (PEP) drugs: These are designed to be taken within 72 hours of potential exposure to HIV. It is a pill ingested once a day for 28 days. Lenacapavir: This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on June 19. Experts say all these preventive measures are good practices, but they note that vaccines are still the most effective.
Business Insider
2 hours ago
- Business Insider
HIV, TB, malaria treatment in Kenya threatened by KSh 11.4B funding reduction
Kenya's Treasury Cabinet Secretary John Mbadi presented the estimates in Parliament on Thursday, showing a drop in HIV, TB, and malaria funding from KSh 28.7 billion in the current financial year to KSh 17.3 billion. This comes after the United States Agency for International Development (USAID) and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) withdrew their financial support earlier this year, leaving Kenya's health sector exposed to severe funding gaps. In March, the Ministry of Health indicated that KSh 13.54 billion was urgently needed to sustain HIV, TB, and malaria programs for the remainder of the year. This included KSh 7.68 billion for the procurement of essential medical commodities and KSh 5.8 billion to maintain the employment of 11,059 frontline healthcare workers. Within the new allocation, the Treasury has included contributions to the Global Fund for HIV, TB, and malaria, alongside KSh 4.6 billion for vaccines and immunization and KSh 500 million for family planning and reproductive health commodities. Concerns rise amid USAID exit However, it remains unclear whether these allocations will be sufficient to cover the funding vacuum created by the exit of USAID and PEPFAR. For years, these donor programs have played a crucial role in supporting Kenya's efforts against HIV and other communicable diseases. Their withdrawal marks a significant setback for ongoing public health interventions. Geopolitical economist Aly-Khan Satchu described the situation as a major stress test for Kenya's health infrastructure. ' To some degree, there is no HIV or vaccine program without PEPFAR,' he said. ' They are going to have to achieve this now in a shock therapy type moment.' The announcement has raised alarm among health stakeholders, who have previously appealed to the government to act swiftly in addressing the budget gap. As the new fiscal plan awaits legislative scrutiny, questions are being raised about how Kenya intends to meet its public health commitments without the financial backing it has relied on for years.
Yahoo
5 hours ago
- Yahoo
'Prostate cancer diagnosis felt like a black hole'
A man diagnosed with incurable prostate cancer said the news felt like falling into a "black hole", as he urged others to check for signs of the disease. Danny Burkey, from Ossett, was diagnosed in 2021, and was told his condition was incurable after a bone scan. The 59-year-old spoke as Prostate Cancer UK launched a campaign urging men to visit their GP with prostate concerns, in the hope of an early diagnosis. Mr Burkey told BBC Radio Leeds: "You think it is always going to happen to somebody else; you just cannot believe it is you." Mr Burkey sought a diagnosis after experiencing symptoms related to prostate cancer. According to the NHS, symptoms can include: Having a sudden urge to urinate Getting up often in the night to urinate Blood in your urine Erectile dysfunction. "I had a blood test, an MRI and a biopsy," Mr Burkey said. Recalling being told his illness was incurable, he said: "You are almost standing next to yourself thinking, I do not know what to do with this. "You just cannot process it." According to Prostate Cancer UK, one in eight men will get prostate cancer. It is now England's most common cancer. Despite the prevalence, the charity's research suggests six in 10 men are concerned about having a Digital Rectal Exam (DRE). Of those, over a third would not speak to a GP about prostate worries because they feared the DRE exam. Mr Burkey urged men to seek a diagnosis despite barriers, saying: "You do not need to have a DRE now. "You can ask your GP for a simple blood test and that gets the ball rolling, it is as simple as that." Earlier this week, the British Association of Urological Surgeons urged GPs to stop using the "outdated" and "inaccurate" DRE as a standard test. They labelled it a "poor test" that deterred men from coming forward. Men are encouraged to use Prostate Cancer UK's 30-second online risk checker and to talk to their GP about the prostate-specific antigen (PSA) blood test. A high level of PSA in the blood can indicate prostate cancer. Research led by Prostate Cancer UK shows that the way prostate cancer is diagnosed - with a PSA blood test followed by an MRI scan - reduces potential harms to men by 79%. Among those to catch the disease early was actor Colin McFarlane. McFarlane, who has appeared in The Dark Knight and Doctor Who, announced he had prostate cancer on the BBC Breakfast sofa in June 2023. He said: "I'm really lucky I caught it early, so I thought if I'm lucky and I know so much about this, I need to try and share this knowledge." McFarlane's friend, theatre director Femi Elufowoju Jr said hearing his story encouraged him to get checked, which led him to also being diagnosed. He thanked McFarlane for saving his life. Despite treatment, including chemotherapy and radiotherapy, Mr Burkey's body has stopped responding to advanced hormone therapy. He said: "Inevitably your body becomes resistant, the cancer becomes resistant to them. "You are constantly having your PSA levels monitored to see how treatments are working. "You are constantly sort of on your toes thinking where am I up to now? "What have I still got left that can be used? "It is a very anxious time. "I do not want another man to be in the position I am in." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North. 'Colin McFarlane saved my life', says director 'Going from cancer doctor to patient was bizarrely reassuring' NHS Prostate Cancer UK
